The Risk G Allele of the Single-Nucleotide Polymorphism rs928413 Creates a CREB1-Binding Site That Activates IL33 Promoter in Lung Epithelial Cells

Alisa M. Gorbacheva 1,2, Kirill V. Korneev 1,2, Dmitry V. Kuprash 1,2 and Nikita A. Mitkin 1,*

1 Laboratory of Intracellular Signaling in Health and Disease, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia; alisamur93@mail.ru (A.M.G.); kirkorneev@yandex.ru (K.V.K.); kuprash@gmail.com (D.V.K.)

2 Biological Faculty, Lomonosov Moscow State University, Moscow 119234, Russia

* Correspondence: mitkin.n.a@gmail.com; Tel.: +7-910-483-99-32

Received: 4 September 2018; Accepted: 21 September 2018; Published: 25 September 2018

Abstract: Cytokine interleukin 33 (IL-33) is constitutively expressed by epithelial barrier cells, and promotes the development of humoral immune responses. Along with other proinflammatory mediators released by the epithelium of airways and lungs, it plays an important role in a number of respiratory pathologies. In particular, IL-33 significantly contributes to pathogenesis of allergy and asthma; genetic variations in the IL33 locus are associated with increased susceptibility to asthma. Large-scale genome-wide association studies have identified minor “G” allele of the single-nucleotide polymorphism rs928413, located in the IL33 promoter area, as a susceptible variant for early childhood and atopic asthma development. Here, we demonstrate that the rs928413(G) allele creates a binding site for the cAMP response element-binding protein 1 (CREB1) transcription factor. In a pulmonary epithelial cell line, activation of CREB1, presumably via the p38 mitogen-activated protein kinases (MAPK) cascade, activates the IL33 promoter containing the rs928413(G) allele specifically and in a CREB1-dependent manner. This mechanism may explain the negative effect of the rs928413 minor “G” allele on asthma development.

Keywords: asthma; lung epithelium; inflammation; p38 MAPK pathway

1. Introduction

Interleukin 33 (IL-33), a member of the interleukin 1 (IL-1) cytokine family, is expressed by endothelial, epithelial, and fibroblast-like cells in barrier tissues and in the sites of inflammation [1,2]. This cytokine also acts as alarmin that is released upon necrotic cell death or stress mediated by infectious agents [3]. Secreted IL-33 binds to heterodimer receptor complex that is located on the surface of multiple myeloid and lymphoid cell types, and is formed by specific receptor ST2 (interleukin 1 receptor-like 1, IL1RL1) and co-receptor interleukin-1 receptor accessory protein (IL-1RAcP). Receptor binding induces activation of NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways [1,4]. IL-33 signaling is associated with induced proliferation of basophils, eosinophils, mast cells, natural killer T (NKT) and type 2 helper T cells, their directed migration, and elevated production of type 2 immune mediators, interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) [5,6]. The IL-33/ST2 pathway is especially accompanied by strong activation of type 2 innate lymphoid cells, which appear to be an important source of IL-5 and IL-13, which are essential for asthma pathogenesis [7].
Numerous studies have demonstrated the particular importance of IL-33 in respiratory and allergic diseases [8,9]. IL-33 level correlates with clinical symptoms in asthmatic patients, with elevated IL-33 protein observed in lung epithelium [9], airway smooth muscle [8], and epithelial cells [10], serum [11] and bronchoalveolar lavage fluid [12]. Elevated IL-33 stimulates systemic T-helper 2 (Th2) type of inflammation and contributes to allergen-induced airway inflammation and hyper-responsiveness, aggravating asthma symptoms [10].

Large-scale genome-wide association studies demonstrated that IL33 locus includes several single-nucleotide polymorphisms (SNPs) associated with asthma development in different populations [13–16]. One of them, rs928413 (A/G), is located in the 5′ upstream region of IL33 gene, and its minor “G” allele was identified as a susceptible variant for early childhood asthma [16] and atopic asthma [17] development. Of note, both homozygous and heterozygous carriers of the rs928413(G) risk allele demonstrated exacerbation of clinically important asthma symptoms [17]. The rs928413(G) allele also demonstrated an association with increased risk of other childhood atopic phenotypes such as hay fever [18], also pointing at possible involvement of this non-coding polymorphism in the development of allergic inflammation.

Based on the available data, we hypothesized that the rs928413(G) allele may be mechanistically linked to asthma susceptibility via transcriptional activation of the IL33 gene. In this paper, we demonstrate that the presence of rs928413(G) allele in the IL33 promoter indeed results in its increased activity in a human lung carcinoma cell line due to binding of the cAMP (cyclic adenosine monophosphate) response element binding protein 1 (CREB1) transcription factor. Our results offer a tentative explanation for the negative effect of rs928413 on asthma development.

2. Results

2.1. Presence of “G” Allele of rs928413 Is Associated with Increased IL33 Promoter Activity

The regulation of human IL33 transcription in different cell types is rather complex, and the available data is rather limited [19,20]. Bioinformatic data on the human IL33 gene available through UCSC Genome Browser (Available online: http://genome.ucsc.edu) is consistent with the activity of the most distant promoter in a broad range of tissues, with epigenetic features which are characteristic of regulatory elements such as DNase-I hypersensitivity sites, major histone modifications (H3K4me3: trimethylation of Histone H3 at lysine 4; H3K4me1: monomethylation of Histone H3 at lysine 4; H3K27ac: acetylation of Histone H3 at lysine 27), and the presence of transcription factors (TF) binding sites spanning the 2.5 kb region upstream of the transcription start site (TSS) (Figure 1A). Single-nucleotide polymorphism rs928413 is located in this area, and its minor G allele was shown to be associated with increased risk of asthma development [16,17]. To evaluate the effect of rs928413 nucleotide variations on IL33 promoter activity, we generated luciferase reporter constructs containing IL33 promoter variants in the pGL3-Basic vector. These constructs were tested in a NCIH-196 human lung carcinoma cell line, which is characterized by constitutive IL33 expression, according to Broad-Novartis Cancer Cell Line Encyclopedia [21]. The reporter construct containing the rs928413(G) allele was significantly more active in this assay (Figure 1B).
2.2. Risk Allele of rs928413 in IL33 Promoter Creates CREB1-Binding Site

The difference in the activity between IL33 promoter variants containing alternative rs928413 alleles is likely associated with the emergence or disappearance of specific transcription factor binding sites (TFBS). We used the PERFECTOS-APE software (Available online: http://opera.autosome.ru/perfectosape, Moscow, Russia) [22] with TFBS models from HOCOMOCO (Available online: http://hocomoco11.autosome.ru) and JASPAR databases (Available online: http://jaspar.genereg.net) to generate a list of candidate transcription factors with the best scores, which included CREB1 (cAMP response element-binding protein 1), FOXF2 (forkhead box protein F2), HNF1A (hepatocyte nuclear factor 1 homeobox A), and E4F1 (E4F transcription factor 1). Of these four, three proteins had no apparent connection to the pathogenesis of asthma: Foxf2 has been shown to play a role in embryogenesis [23], in particular in the development of gut [24] and secondary palate [25], HNF1A is involved in control of liver-specific gene expression [26] and in glucose metabolism [27], and E4F1 is necessary for the proliferation and survival of embryonic, stem, and cancer cells [28–30]. On the other hand, phosphorylated CREB1 is known as an important activator of various genes encoding chemokines and pro-inflammatory cytokines that are biologically relevant to asthma [31]. Importantly, CREB has been implicated in asthmatic pathogenesis [32–34]. However, the physiological significance of CREB phosphorylation in lung epithelium has not been sufficiently studied, and functional mechanisms mediating the association between CREB phosphorylation and asthma remain unclear [35]. We hypothesized that the binding site for CREB1 created by the risk rs928413(G) allele resulting in enhanced IL33 transcription may provide a mechanistical explanation for this association.

We used a pull-down assay with nuclear extracts from NC Ich-196 cell line to investigate the influence of rs928413 on CREB1 binding to the IL33 promoter. We created four variants of the IL33 gene promoter region (−2500/−2300), containing either common “A” or risk “G” rs928413 allele, and either the original or mutated CREB1 site (Figure 2). The probe containing the rs928413(G)
allele demonstrated high precipitation efficiency with anti-CREB1 antibodies, while the level of precipitation of the fragment containing the “A” allele did not significantly differ from that of control probes. Thus, a CREB1-binding site is indeed present in the human IL33 promoter containing risk rs928413(G) allele.

Figure 2. Rs928413(G) is associated with CREB1 binding. (A) Schematic illustration of rs928413 location in IL33 promoter and the amplicon used for the pull-down assay. (B) Position weight matrix of CREB1-binding site and schematic illustration of its mutagenesis. Green arrows indicate nucleotides changes. (C) Efficiency of CREB1 binding to different variants of IL33 promoter (rs928413 variants shown in red color) as estimated by pull-down assay using nuclear extracts from NCIH-196 cells. Data was normalized to control amplicon after subtraction of the background signal (see Section 4). The result of five independent experiments is represented. * p < 0.01.

2.3. CREB1 Activation Is Associated with Elevated IL33 Promoter Activity

Activation of CREB by phosphorylation at serine 133 is promoted by various type of kinases, including mitogen-activated protein kinases (MAPKs) [31,36]; p38 MAPK is hyper-activated in the cells of patients with severe asthma [37,38]. The activity of p38 MAP kinases is, in turn, induced by inflammatory mediators [39] including TNF (tumor necrosis factor), which is also involved in asthma pathogenesis [40]. In particular, CREB phosphorylation through p38 MAP kinases after TNF stimulation was demonstrated in human airway epithelial cells [41] and in primary lung fibroblasts [35]. Therefore, we tested the effects of TNF in our model system.

As expected, treatment with TNF for 24 h did not affect the level of CREB1 mRNA in NCIH-196 cells (Figure 3A), while phosphorylated CREB1 (p-CREB1) was significantly activated by the cytokine (Figure 3B). Transfection with specific siRNA resulted in a strong decrease in both CREB1 mRNA and p-CREB1 levels, regardless of the TNF presence (Figure 3A,B).
Figure 3. TNF-induced activation promotes phosphorylation of CREB1 in lung cancer cells. Activation by TNF (tumor necrosis factor) (100 ng/mL, 24 h) does not influence the level of CREB1 expression (A) but results in an increase in phosphorylated CREB1 protein (B). In (A), NCIH-196 cells were: “-”, without addition of any siRNA; “+ siRNA”, transfected with CREB1-specific siRNA; “+ scrambled RNA” transfected with scrambled siRNA. In (B), NCIH-196 cells were: “NCIH-196 + TNF”, incubated with TNF; “NCIH-196”, without TNF or siRNA; “NCIH-196 + TNF + siRNA”, transfected with siRNA and incubated with TNF; “NCIH-196 + siRNA”, transfected with siRNA only. Real-time PCR data is determined using the ΔΔCt approach, normalized to β-actin and represented as Mean ± SEM (five replicate experiments). * \( p < 0.01 \). Western blot data is a representative image of three independent experiments.

In order to determine the role of CREB1 in IL33 promoter activity, we combined the panel of reporter vectors bearing rs928413 allelic variants and CREB1-binding site mutations with TNF activation and siRNA-mediated CREB1 knockdown. As shown on Figure 4, TNF activation selectively and specifically increased the activity of the IL33 promoter construct containing rs928413(G) allele and functional CREB1-binding site. Both the presence of rs928413(A) allele and the CREB1 site mutation made the reporter unresponsive to TNF. Activation was also completely abrogated by the addition of CREB1-specific siRNA. These results indicate that the potentially negative role of the minor rs928413(G) allele in asthma may be mechanistically explained by IL33 promoter stimulation with CREB1 transcription factor, that can be further activated by TNF.
with the presence of the CREB1 binding site and increased IL33 distal promoter area of the in the airway and lung epithelium is supposed to be associated with the maintenance of mucosal immunity [57], expansion of type 2 innate lymphoid cells [58], mobilization of eosinophils [59], and asthma development. It stimulates airway hyper-responsiveness [56] and induction of Th2-type adaptive immunity [57], expansion of type 2 innate lymphoid cells [58], mobilization of eosinophils [59], mast cells and basophils activation [60,61], and an increase in IgE production by B-cells [62].

 activated receptors that can be stimulated directly by pathogens and by allergens during the sensitization phase of asthma [44–47]. Activated epithelial cells release chemokines [48,49], danger-associated molecular patterns (DAMPs) [50,51] and cytokines [48,52,53] which attract various immune cells to the airways and lungs, and modulate their response [7,54,55]. IL-33 is considered to be one of the crucial epithelial-derived cytokines involved in allergic inflammation and asthma development. It stimulates airway hyper-responsiveness [56] and induction of Th2-type adaptive immunity [57], expansion of type 2 innate lymphoid cells [58], mobilization of eosinophils [59], mast cells and basophils activation [60,61], and an increase in IgE production by B-cells [62]. IL-33 blockade contributes to the alleviation of allergic rhinitis symptoms [63], and suppresses the development of asthma in mouse models [64–66]. Accordingly, elevated expression of IL33 in the airway and lung epithelium is supposed to be associated with the maintenance of mucosal inflammatory conditions and the aggravation of pathological changes during asthma.

In the present work, we characterized a possible functional role of SNP rs928413 located in the distal promoter area of the IL33 gene. We demonstrated that the risk rs928413(G) allele is associated with the presence of the CREB1 binding site and increased IL33 promoter activity, which can be

![Figure 4](image-url)

**Figure 4.** The rs928413(G) allele mediates CREB1-dependent IL33 promoter stimulation of lung cancer cells by TNF. Reporter constructs contained Firefly luciferase gene under the control of indicated versions of the IL33 promoter. siRNA for the CREB1 knockdown was electroporated 24 h prior to electroporation of the reporter. TNF (100 ng/mL) was added at the time of both electroporations. The data shown (mean ± SEM) was obtained in five independent experiments and normalized to Renilla luciferase activity. * p < 0.01.

3. Discussion

The epithelium of airways and lungs is one of the most important physical barriers between external environment and the human organism. Due to permanent interaction with pathogenic microorganisms and inhaled antigens, lung epithelial cells (ECs) act as mediators of the host’s defense [42], and often become a key participant in the development of allergic inflammation and asthma pathogenesis [43]. Lung ECs express a wide repertoire of pattern-recognition receptors and protease activated receptors that can be stimulated directly by pathogens and by allergens during the sensitization phase of asthma [44–47]. Activated epithelial cells release chemokines [48,49], danger-associated molecular patterns (DAMPs) [50,51] and cytokines [48,52,53] which attract various immune cells to the airways and lungs, and modulate their response [7,54,55]. IL-33 is considered to be one of the crucial epithelial-derived cytokines involved in allergic inflammation and asthma development. It stimulates airway hyper-responsiveness [56] and induction of Th2-type adaptive immunity [57], expansion of type 2 innate lymphoid cells [58], mobilization of eosinophils [59], mast cells and basophils activation [60,61], and an increase in IgE production by B-cells [62].
enhanced by TNF, presumably via p38 MAPK cascade. As already noted, increased activation of this pathway was observed in the asthmatic airways; the extent of the activation correlated with the severity of the disease [37,38]. Furthermore, p38 kinase appears to play an important role in asthma exacerbation by controlling production of proinflammatory cytokines and chemokines by epithelial cells [67]. Elevated CREB1 activity has been linked by many studies to the regulation of proinflammatory cytokines production [68,69] and to the pathogenesis of respiratory diseases such as chronic obstructive pulmonary disease (COPD) [70]. In the case of asthma, the level of CREB1 phosphorylation in bronchial epithelium of asthmatic patients correlated with the inflammatory status, and consequently, could be used as a prognostic marker [34]. CREB1 binding to a site in the IL33 promoter created by the rs928413(G) allele is consistent with the observation of more pronounced clinical asthma symptoms in patients carrying both homozygous and heterozygous rs928413(G) variants [17].

In conclusion, our data suggest that a mechanism that may explain the observed association of rs928413 polymorphism with asthma susceptibility. Elevated production of IL-33 by damaged or stressed cells of the barrier epithelium could promote airway hyper-responsiveness and development of inflammatory response during the initiation and persistence of asthma. The proposed mechanism corroborates the critical role of epithelium in asthmatic pathogenesis reported in an increasing number of studies. In the future, it is important to assess the correlation between CREB1 binding to the rs928413(G) allele with IL-33 production in primary cells, and with disease symptoms in asthmatic patients.

4. Materials and Methods

4.1. Cell Lines

A NCIH-196 human lung carcinoma cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Thermo Scientific, Waltham, MA, USA). Preliminary experiments with various concentrations of recombinant human TNF (tumor necrosis factor) (kindly provided by Daniela N. Männel, Institute of Immunology, University of Regensburg, Regensburg, Germany) (1, 10, 100 and 300 ng/mL) for 24 and 48 h demonstrated that 100 ng/mL TNF for 24 h yielded the strongest increase in IL33 expression, as measured by real-time PCR. Therefore, this treatment regimen was used in further experiments.

4.2. Ethical Approval

The Scientific Council of the Engelhardt Institute of Molecular Biology declared no ethical approval requirements for experiments performed in this study, because only commercially available cell lines were used.

4.3. Luciferase Reporter Construct

The human IL33 promoter region containing nucleotides −2512 to +79 bp from the transcription start site (TSS) was amplified by PCR using genomic DNA isolated from NCIH-196 cells and specific oligonucleotide primers containing HindIII/NcoI restriction sites. IL33 promoter variants containing the minor (G) allele of rs928413 and mutations of the CREB1 binding site were amplified by overlap PCR, and verified by Sanger sequencing. Variants of IL33 promoter were cloned into pGL3-basic luciferase reporter vector (Promega, Madison, WI, USA) using HindIII and NcoI restriction sites. The sequences of the primers are indicated in Table S1.

4.4. NCIH-196 Transfection and Luciferase Reporter Assay

Cells were transfected with 1.8 µg of plasmid DNA and 0.2 µg of pRL-CMV Renilla luciferase control vector using X-treme Gene HP DNA Transfection Reagent (Roche, Basel, Switzerland) according
to manufacturer’s protocol. Firefly luciferase activity was measured as described [71], and normalized to the activity of Renilla luciferase in order to account for the variations in cell transfection and lysis efficiencies.

4.5. Pull-Down Assay

Two hundred bp fragments of the IL33 promoter (−2500 to −2300 from the TSS) containing rs928413 were amplified by PCR using DNA templates containing combinations of the A and G rs928413 alleles with either intact or mutant CREB1 binding site. An irrelevant DNA fragment that did not include any predicted CREB1-binding sites was used as a negative control. All PCR products were verified by sequencing; sequences of PCR primers are represented in Table S1. Isolation of nuclear extracts, formation and immunoprecipitation of DNA-protein complexes, and the evaluation of bound DNA probes by RT-PCR were performed as described [72]. Rabbit polyclonal anti-CREB1 antibody (ab31387, Abcam, Cambridge, UK) was precipitated with pre-blocked magnetic beads (Thermo Scientific, Waltham, MA, USA). The background signal was determined using a negative control DNA fragment and binding reactions without nuclear extracts, without antibodies and with rabbit IgG isotype control. All data was normalized to the signal obtained with negative control DNA probe.

4.6. CREB1 Knockdown Using siRNA

Commercially synthesized single-stranded RNAs (Syntol, Moscow, Russia) were annealed as previously described [73]. NCIH-196 cells were transfected with siRNA duplexes (500 pmol of per 5 million cells) 48 h before transfection with the luciferase constructs and a further 200 pmol to extend the silencing effect. The measurement of CREB1 mRNA level by RT-PCR was performed as described [74]. Of three published pairs of siRNAs against CREB1 [75], one mediated a significant decrease in CREB1 mRNA level. The sequences of the siRNA and the CREB1-specific PCR primers are represented in Table S1.

4.7. Western Blot Analysis

Protocols of total cell lysates preparation, electrophoresis, and transfer to the nitrocellulose membrane were previously described [76]. Membranes were blocked with 5% non-fat dry milk, and incubated with anti-CREB1 (phospho S133) antibodies (ab32096, Abcam, Cambridge, UK) at 1:2000 dilution and anti-β-actin antibodies (ab8229, Abcam, Cambridge, UK) at 1:3000 dilution as a loading control. The bands were visualized using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific, Waltham, MA, USA) and ChemiDoc XRS + system (BioRad, Hercules, CA, USA).

4.8. Statistical Analysis

We used Microsoft Excel for statistical analyses. Statistical significance was determined using two-tailed unpaired Student’s t-test. Data were represented as mean ± SEM.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/10/2911/s1.

Author Contributions: Conceptualization, A.M.G. and N.A.M.; methodology, A.M.G.; investigation, A.M.G. and K.V.K.; resources, D.V.K.; writing—original draft preparation, A.M.G.; visualization, A.M.G.; supervision, N.A.M. and D.V.K.; project administration, N.A.M.; funding acquisition, D.V.K.

Funding: Most of the experiments (Figures 1–3) were supported by grant 14-14-01140 from Russian Science Foundation. Point mutagenesis of promoter constructs (Figure 4) were supported by the Program of fundamental research for state academies for 2013–2020, research topic 01201363823.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Schmitz, J.; Owyang, A.; Oldham, E.; Song, Y.; Murphy, E.; McClanahan, T.K.; Zurawski, G.; Moshrefi, M.; Qin, J.; Li, X.; et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 2005, 23, 479–490. [CrossRef] [PubMed]

2. Pichery, M.; Mirey, E.; Mercier, P.; Lefrancais, E.; Dujardin, A.; Ortega, N.; Girard, J.P. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel II-33-LacZ gene trap reporter strain. *J. Immunol.* 2012, 188, 3488–3495. [CrossRef] [PubMed]

3. Cayrol, C.; Girard, J. IL-33: An alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. *Curr. Opin. Immunol.* 2014, 31, 31–37. [CrossRef] [PubMed]

4. Lott, J.M.; Sumpter, T.L.; Turnquist, H.R. New dog and new tricks: Evolving roles for IL-33 in type 2 immunity. *J. Leukoc. Biol.* 2015, 97, 1037–1048. [CrossRef] [PubMed]

5. Smith, D.E. IL-33: A tissue derived cytokine pathway involved in allergic inflammation and asthma. *Clin. Exp. Allergy* 2009, 40, 200–208. [CrossRef] [PubMed]

6. Liew, F.Y.; Pitman, N.J.; McInnes, I.B. Disease-associated functions of IL-33: The new kid in the IL-1 family. *Nat. Rev. Immunol.* 2010, 10, 103–110. [CrossRef] [PubMed]

7. Neill, D.R.; Wong, S.H.; Bellosi, A.; Flynn, R.J.; Daly, M.; Langford, T.K.A.; Fallon, P.G.; Pannell, R.; et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. *Nature* 2010, 464, 1367–1370. [CrossRef] [PubMed]

8. Préfontaine, D.; Lajoie-Kadoch, S.; Foley, S.; Audusseau, S.; Olivenstein, R.; Halayko, A.J.; Lemière, C.; Martin, J.G.; Hamid, Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. *J. Immunol.* 2009, 183, 5094–5103. [CrossRef] [PubMed]

9. Kurowska-Stolarska, M.; Stolarski, B.; Kewin, P.; Murphy, G.; Corrigan, C.J.; Ying, S.; Pitman, N.; Mirchandani, A.; Rana, B.; van Rooijen, N.; et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. *J. Immunol.* 2009, 183, 6469–6477. [CrossRef] [PubMed]

10. Préfontaine, D.; Nadigel, J.; Chouiali, F.; Audusseau, S.; Semlali, A.; Chakir, J.; Martin, J.G.; Hamid, Q. Increased IL-33 expression by epithelial cells in bronchial asthma. *J. Allergy Clin. Immunol.* 2010, 125, 752–754. [CrossRef] [PubMed]

11. Raiszadeh Jahromi, S.; Mahesh, P.A.; Jayaraj, B.S.; Madhunapantula, S.R.V.; Holla, A.D.; Vishweswaraiah, S.; Ramachandra, N.B. Serum levels of IL-10, IL-12F and IL-33 in patients with asthma: A case-control study. *J. Asthma* 2014, 51, 1004–1013. [CrossRef] [PubMed]

12. Christianson, C.A.; Goplen, N.P.; Zafar, I.; Irvin, C.; Good, J.T.; Rollins, D.R.; Gorenltala, B.; Liu, W.; Gorska, M.M.; Chu, H.W.; et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. *J. Allergy Clin. Immunol.* 2015, 136, 59–68. [CrossRef] [PubMed]

13. Gudbjartsson, D.F.; Bjornsdottir, U.S.; Halapi, E.; Helgadottir, A.; Sulem, P.; Jonsdottir, G.M.; Thorleifsson, G.; Helgadottir, H.; Steinthorsdottir, V.; Stefansson, H.; et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat. Genet.* 2009, 41, 342–347. [CrossRef] [PubMed]

14. Moffatt, M.; Gut, I.; Demenais, F.; Strachan, D.; Bouzigon, E.; Heath, S. A Large-Scale, Consortium-Based Genomewide Association Study of Asthma. *N. Engl. J. Med.* 2010, 363, 525–527. [CrossRef] [PubMed]

15. Torgerson, D.G.; Ampleford, E.J.; Chiu, G.Y.; Gauderman, W.J.; Gignoux, C.R.; Graves, P.E.; Himes, B.E.; Levin, A.M.; Mathias, R.A.; Hancock, D.B.; et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. *Nat. Genet.* 2011, 43, 887–892. [CrossRef] [PubMed]

16. Bonnellykke, K.; Slieman, P.; Nielsen, K.; Kreiner-moller, E.; Mercader, J.M.; Belgrave, D.; Dekker, H.T.; Den Husby, A.; Sevelsted, Á.; Faura-tellez, G.; et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for severe childhood wheezing as a consequence of childhood asthma. *Pediatr. Allergy Immunol.* 2016, 27, 687–695. [CrossRef] [PubMed]
19. Tominaga, S.; Hayakawa, M.; Tsuda, H.; Ohta, S.; Yanagisawa, K. Presence of a novel exon 2E encoding a putative transmembrane protein in human IL-33 gene. Biochem. Biophys. Res. Commun. 2013, 430, 969–974. [CrossRef] [PubMed]

20. Tsuda, H.; Komine, M.; Tominaga, S.; Ohtsuki, M. Identification of the promoter region of human IL-33 responsive to induction by IFNγ. J. Dermatol. Sci. 2017, 85, 137–140. [CrossRef] [PubMed]

21. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Kryukov, G.V.; Sonkin, D.; Reddy, A.; Liu, M.; et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 463, 603–607. [CrossRef] [PubMed]

22. Vorontsov, I.E.; Kulakovskiy, I.V.; Khimulya, G.; Nikolaeva, D.D.; Makeev, V.J. PERFECTOS-APE: Predicting regulatory functional effect of SNPs by approximate P-value estimation. In Proceedings of the Bioinformatics 2015 6th International Conference on Bioinformatics Models, Methods and Algorithms, Lisbon, Portugal, 12–15 January 2015; pp. 102–108. [CrossRef]

23. Aitola, M.; Carlsson, P.; Mahlapuu, M.; Enerbäck, S.; Pelto-Huikko, M. Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal. Dev. Dyn. 2000, 218, 136–149. [CrossRef]

24. Ormestad, M.; Astorga, J.; Landgren, H.; Wang, T.; Carlsson, P. Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 2006, 133, 833–843. [CrossRef] [PubMed]

25. Wang, T.; Tamakoshi, T.; Uezato, T.; Shu, F.; Kanzaki-Kato, N.; Fu, Y.; Koseki, H.; Yoshida, N.; Sugiyama, T.; Miura, N. Forkhead transcription factor Foxf2 (LUN)-deficient mice exhibit abnormal development of secondary palate. Dev. Biol. 2003, 259, 83–94. [CrossRef]

26. Courtois, G.; Morgan, J.; Campbell, L.; Fourel, G.; Crabtree, G. Interaction of a Liver-Specific Nuclear Factor with the Fibrinogen and α1-Antitrypsin Promoters. Science 1987, 238, 688–692. [CrossRef] [PubMed]

27. Pedersen, K.; Chhabra, K.; Nguen, V.; Lazartigues, E. The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. Biochim. Biophys. Acta 2013, 43, 743–752. [CrossRef] [PubMed]

28. Le Cam, L.; Lacroix, M.; Ciemerych, M.A.; Sardet, C.; Sicinski, P. The E4F Protein Is Required for Mitotic Progression during Embryonic Cell Cycles. Mol. Cell. Biol. 2004, 24, 6467–6475. [CrossRef] [PubMed]

29. Chagroui, J.; Niessen, S.; Lessard, J.; Girard, S.; Cousol, P.; Sauvageau, G. p120E4F-1: A novel candidate factor for mediating Bmi-1 function in hematopoietic stem cells. Blood 2004, 104, 307. [CrossRef]

30. Hatchi, E.; Rodier, G.; Lacroix, M.; Caramel, J.; Kirsh, O.; Jacquet, C.; Schreph, E.; Lagarrigue, S.; Linares, L.K.; Lledo, G.; et al. E4F1 deficiency results in oxidative stress-mediated cell death of leukemic cells. J. Exp. Med. 2011, 208, 1403–1417. [CrossRef] [PubMed]

31. Shaywitz, A.J.; Greenberg, M.E. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 1999, 68, 821–861. [CrossRef] [PubMed]

32. Barnes, P.J.; Adcock, I.M. Transmission factors and asthma. Eur. Respir. J. 1998, 12, 221–234. [CrossRef] [PubMed]

33. Bartel, S.; Schulz, N.; Alessandri, F.; Schamberger, A.C.; Pagel, P.; Theis, F.J.; Milger, M.; Noessner, E.; Stick, S.M.; Kiic, A.; et al. Pulmonary microRNA profiles identify involvement of Creb1 and Sec14l3 in bronchial epithelial changes in allergic asthma. Sci. Rep. 2017, 7, 46026. [CrossRef] [PubMed]

34. Chiappara, G.; Chanez, P.; Bruno, A.; Pace, E.; Pompeo, F.; Bousquet, J.; Bonsignore, G.; Gjomarkaj, M. Variable p-CREB expression depicts different asthma phenotypes. Allergy Eur. J. Allergy Clin. Immunol. 2007, 62, 787–794. [CrossRef] [PubMed]

35. Koga, Y.; Hisada, T.; Ishizuka, T.; Usugi, M.; Ono, A.; Yamato, M.; Kamide, Y.; Aoki-Saito, H.; Tsurumaki, H.; Dobashi, K.; et al. CREB regulates TNF-α-induced GM-CSF secretion via p38 MAPK in human lung fibroblasts. Allergol. Int. 2016, 65, 6–13. [CrossRef] [PubMed]

36. Wen, A.Y.; Sakamoto, K.M.; Miller, L.S. The Role of the Transcription Factor CREB in Immune Function. J. Immunol. 2010, 185, 6413–6419. [CrossRef] [PubMed]

37. Liu, W.; Liang, Q.; Balzar, S.; Wenzel, S.; Gorska, M.; Alam, R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J. Allergy Clin. Immunol. 2008, 121, 893–902. [CrossRef] [PubMed]

38. Barnes, P.J. New therapies for asthma: Is there any progress? Trends Pharmacol. Sci. 2010, 31, 335–343. [CrossRef] [PubMed]
39. Sabio, G.; Davis, R.J. TNF and MAP kinase signalling pathways. *Semin. Immunol.* **2014**, *26*, 237–245. [CrossRef] [PubMed]

40. Ying, S.; Robinson, D.S.; Varney, V.; Meng, Q.; Tsicopoulos, A.; Mqbel, R.; Durham, S.R.; Kay, A.B.; Hamid, Q. TNF alpha mRNA expression in allergic inflammation. *Clin. Exp. Allergy* **1991**, *21*, 745–750. [CrossRef] [PubMed]

41. Song, K.S.; Lee, W.; Chung, C.; Koo, J.S.; Yang, E.J.; Choi, Y.; Yoon, J.; Song, K.S.; Lee, W.; Chung, K.C.; et al. Mechanisms of Signal Transduction: Interleukin-1β and Tumor Necrosis Factor-α Induce MUC5AC Overexpression through a Mechanism Involving ERK/p38 Mitogen-activated Protein Kinases-MSK1-CREB Activation in Human Airway Epithelial Cells. *J. Biol. Chem.* **2003**, *278*, 23243–23250. [CrossRef] [PubMed]

42. Whitsett, J.A.; Alenghat, T. Respiratory epithelial cells orchestrate pulmonary innate immunity. *Nat. Immunol.* **2015**, *16*, 27–35. [CrossRef] [PubMed]

43. Lambrecht, B.N.; Hammad, H. The immunology of asthma. *Nat. Immunol.* **2015**, *16*, 45–56. [CrossRef]

44. Uehara, A.; Fujimoto, Y.; Fukase, K.; Takada, H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. *Mol. Immunol.* **2007**, *44*, 3100–3111. [CrossRef] [PubMed]

45. Kovach, M.A.; Standiford, T.J. Toll like receptors in diseases of the lung. *Int. Immunopharmacol.* **2011**, *11*, 1399–1406. [CrossRef] [PubMed]

46. Leiva-Juárez, M.M.; Kolls, J.K.; Evans, S.E. Lung epithelial cells: Therapeutically inducible effectors of antimicrobial defense. *Mucosal Immunol.* **2018**, *11*, 21–34. [CrossRef] [PubMed]

47. Asokananthan, N.; Graham, P.T.; Fink, J.; Knight, D.A.; Bakker, A.J.; McWilliam, A.S.; Thompson, P.J.; Stewart, G.A. Activation of Protease-Activated Receptor (PAR)-1, PAR-2, and PAR-4 Stimulates IL-6, IL-8, and Prostaglandin E2 Release from Human Respiratory Epithelial Cells. *J. Immunol.* **2002**, *168*, 3577–3585. [CrossRef] [PubMed]

48. Hammad, H.; Chieppa, M.; Perros, F.; Willart, M.A.; Germain, R.N.; Lambrecht, B.N. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nat. Med.* **2009**, *15*, 410–416. [CrossRef] [PubMed]

49. Nathan, A.T.; Peterson, E.A.; Chakir, J.; Wills-Karp, M. Innate immune responses of airway epithelium to house dust mite are mediated through β-glucan-dependent pathways. *J. Allergy Clin. Immunol.* **2009**, *123*, 612–618. [CrossRef] [PubMed]

50. Idzko, M.; Hammad, H.; Van Nimwegen, M.; Kool, M.A.M.; Musken, F.; Hoogsteden, H.C.; Luttmann, W.; Ferrari, D.; Di Virgilio, F.; et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. *Nat. Med.* **2007**, *13*, 913–919. [CrossRef] [PubMed]

51. Kool, M.; Willart, M.A.M.; van Nimwegen, M.; Bergen, I.; Pouliot, P.; Virchow, J.C.; Rogers, N.; Osorio, F.; Reis e Sousa, C.; Hammad, H.; et al. An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma. *Immunity* **2011**, *34*, 527–540. [CrossRef] [PubMed]

52. Herre, J.; Gronlund, H.; Brooks, H.; Hopkins, L.; Waggoner, L.; Burton, B.; Gangloff, M.; Opaleye, O.; Chiwers, E.R.; Fitzgerald, K.; et al. Allergens as Immunomodulatory Proteins: The Cat Dander Protein Fel d 1 Enhances TLR Activation by Lipid Ligands. *J. Immunol.* **2013**, *191*, 1529–1535. [CrossRef] [PubMed]

53. Millien, V.O.; Lu, W.; Shaw, J.; Yuan, X.; Mak, G.; Roberts, L.; Song, L.Z.; Knight, J.M.; Creighton, C.J.; Luong, A.; et al. Cleavage of Fibrinogen by Proteinases Elicits Allergic Responses Through Toll-Like Receptor 4. *Science* **2013**, *341*, 792–796. [CrossRef] [PubMed]

54. Lambrecht, B.N.; Hammad, H. Biology of Lung Dendritic Cells at the Origin of Asthma. *Immunity* **2009**, *31*, 412–424. [CrossRef] [PubMed]

55. Schneider, E.; Petit-Berton, A.F.; Bricard, R.; Levassuer, M.; Ramadan, A.; Girard, J.P.; Herbelin, A.; Dy, M. IL-33 Activates Unprimed Murine Basophils Directly In Vitro and Induces Their In Vivo Expansion Indirectly by Promoting Hematopoietic Growth Factor Production. *J. Immunol.* **2009**, *183*, 3591–3597. [CrossRef] [PubMed]

56. Kaur, D.; Gomez, E.; Doe, C.; Berair, R.; Woodman, L.; Saunders, R.; Hollins, F.; Rose, F.R.; Amrani, Y.; May, R.; et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: Airway smooth muscle crosstalk. *Allergy Eur. J. Allergy Clin. Immunol.* **2015**, *70*, 556–567. [CrossRef] [PubMed]
57. Kurowska-Stolarska, M.; Kewin, P.; Murphy, G.; Russo, R.C.; Stolarski, B.; Garcia, C.C.; Komai-Koma, M.; Pitman, N.; Li, Y.; McKenzie, A.N.J.; et al. IL-33 Induces Antigen-Specific IL-5+ T Cells and Promotes Allergic-Induced Airway Inflammation Independent of IL-4. J. Immunol. 2008, 181, 4780–4790. [CrossRef] [PubMed]

58. Bartemes, K.R.; Iijima, K.; Kobayashi, T.; Kephart, G.M.; McKenzie, A.N.; Kita, H. IL-33-Responsive Lineage-CD25+ CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs. J. Immunol. 2012, 188, 1503–1513. [CrossRef] [PubMed]

59. Stolarski, B.; Kurowska-Stolarska, M.; Kewin, P.; Xu, D.; Liew, F.Y. IL-33 Exacerbates Eosinophil-Mediated Airway Inflammation. J. Immunol. 2010, 185, 3472–3480. [CrossRef] [PubMed]

60. Lunderius-Andersson, C.; Enoksson, M.; Nilsson, G. Mast cells respond to cell injury through the recognition of IL-33. Front. Immunol. 2012, 3, 1–9. [CrossRef] [PubMed]

61. Suzukawa, M.; Ikura, M.; Koketsu, R.; Nagase, H.; Tamura, C.; Komiya, A.; Nakae, S.; Matsushima, K.; Ohta, K.; Yamamoto, K.; et al. An IL-1 Cytokine Member, IL-33, Induces Human Basophil Activation via Its ST2 Receptor. J. Immunol. 2008, 181, 5981–5989. [CrossRef] [PubMed]

62. Komai-Koma, M.; Brombacher, F.; Pushparaj, P.N.; Arendse, B.; Alexander, J.; Chaudhuri, R.; Thomson, N.C.; McKenzie, A.N.J.; McInnes, I.; et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy Eur. J. Allergy Clin. Immunol. 2012, 67, 1118–1126. [CrossRef] [PubMed]

63. Kim, Y.H.; Yang, T.Y.; Park, C.S.; Ahn, S.H.; Son, B.K.; Kim, J.H.; Lim, D.H.; Jang, T.Y. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy Eur. J. Allergy Clin. Immunol. 2012, 67, 183–190. [CrossRef] [PubMed]

64. Willart, M.A.M.; Deswarte, K.; Pouliot, P.; Braun, H.; Bejaert, R.; Lambrecht, B.N.; Hammad, H. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J. Exp. Med. 2012, 209, 1505–1517. [CrossRef] [PubMed]

65. Yan, S.; Ghosh, P.; Kubota, H.; Buchholz, M.; Longo, D.L. Effect of promoter methylation on the regulation of IFN-gamma gene during in vitro differentiation of human peripheral blood T cells into a Th2 population. J. Immunol. 2003, 171, 2510–2516. [CrossRef] [PubMed]

66. Chava, K.R.; Karpurapu, M.; Wang, D.; Bhanooori, M.; Kundumani-Sridharan, V.; Zhang, Q.; Ichiki, T.; Glasgow, W.C.; Rao, G.N. CREB-mediated IL-6 expression is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 809–815. [CrossRef] [PubMed]

67. Hashimoto, S.; Matsumoto, K.; Gon, Y.; Maruoka, S.; Kujime, K.; Hayashi, S.; Takeshita, I.; Horie, T. p38 MAP kinase regulates TNF-alpha-, IL-1 alpha- and PAF-induced RANTES and GM-CSF production by human bronchial epithelial cells. Clin. Exp. Allergy 2000, 30, 48–55. [CrossRef] [PubMed]

68. Mroz, R.M.; Holownia, A.; Chyczewska, E.; Drost, E.M.; Braszko, J.J.; Noraz, S.; Donaldson, K.; Macnee, W. Cytoplasm-Nuclear Trafficking of Creb and Creb Phosphorylation at Ser133 During Therapy of Chronic Obstructive Pulmonary Disease. J. Physiol. Pharmacol. 2007, 58, 437–444. [PubMed]

69. Korneev, K.V.; Kondakova, A.N.; Sviriaeva, E.N.; Mitkin, N.A.; Palmigiano, A.; Kruglov, A.A.; Telegin, G.B.; Drutschaya, M.S.; Sturiale, L.; Garozzo, D.; et al. Hypoacylated LPS from Foodborne Pathogen Campylobacter jejuni Induces Moderate TLR4-Mediated Inflammatory Response in Murine Macrophages. Front. Cell. Infect. Microbiol. 2018, 8, 58. [CrossRef] [PubMed]

70. Mitkin, N.A.; Muratova, A.M.; Schwartz, A.M.; Kuprash, D.V. The A allele of the Single-Nucleotide Polymorphism rs630923 creates a Binding site for MEF2C resulting in reduced CXCR5 Promoter activity in B-cell lymphoblastic cell lines. Front. Immunol. 2016, 7, 515. [CrossRef] [PubMed]
73. Mitkin, N.A.; Muratova, A.M.; Sharonov, G.V.; Korneev, K.V.; Sviriaeva, E.N.; Mazurov, D.; Schwartz, A.M.; Kuprash, D.V. p63 and p73 repress CXCR5 chemokine receptor gene expression in p53-deficient MCF-7 breast cancer cells during genotoxic stress. *Biochim. Biophys. Acta Gene Regul. Mech.* 2017, 1860, 1169–1178. [CrossRef] [PubMed]

74. Mitkin, N.A.; Muratova, A.M.; Korneev, K.V.; Pavshintsev, V.V.; Rumyantsev, K.A.; Vagida, M.S.; Uvarova, A.N.; Afanasyeva, M.A.; Schwartz, A.M.; Kuprash, D.V. Protective C allele of the single-nucleotide polymorphism rs1335532 is associated with strong binding of Ascl2 transcription factor and elevated CD58 expression in B-cells. *Biochim. Biophys. Acta Mol. Basis Dis.* 2018, 1864, 3211–3220. [CrossRef] [PubMed]

75. Hasson, S.A.; Kane, L.A.; Yamano, K.; Huang, C.H.; Sliter, D.A.; Buehler, E.; Wang, C.; Heman-Ackah, S.M.; Hessa, T.; Guha, R.; et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. *Nature* 2013, 504, 291–295. [CrossRef] [PubMed]

76. Afanasyeva, M.A.; Britanova, L.V.; Korneev, K.V.; Mitkin, N.A.; Kuchmiy, A.A.; Kuprash, D.V. Clusterin is a potential lymphotoxin beta receptor target that is upregulated and accumulates in germinal centers of mouse spleen during immune response. *PLoS ONE* 2014, 9, e98349. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).